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Abstract Although KIT mutations are present in 20–25%
of cases of t(8;21)(q22;q22) acute myeloid leukemia
(AML), concurrent development of systemic mastocytosis
(SM) is exceedingly rare. We examined the clinicopatho-
logic features of SM associated with t(8;21)(q22;q22) AML
in ten patients (six from our institutions and four from
published literature) with t(8;21) AML and SM. In the
majority of these cases, a definitive diagnosis of SM was
made after chemotherapy, when the mast cell infiltrates
were prominent. Deletion 9q was an additional cytogenetic
abnormality in four cases. Four of the ten patients failed
to achieve remission after standard chemotherapy and
seven of the ten patients have died of AML. In the two
patients who achieved durable remission after allogeneic
hematopoietic stem cell transplant, recipient-derived neo-
plastic bone marrow mast cells persisted despite leukemic
remission. SM associated with t(8;21) AML carries a
dismal prognosis; therefore, detection of concurrent SM
at diagnosis of t(8;21) AML has important prognostic
implications.
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Introduction
The t(8;21)(q22;q22) occurs in about 5% of all acute
myeloid leukemias (AML) and in 10% of cases of AML
with FAB-M2 morphology [1]. The Runt domain transcrip-
tion factor RUNX1 (AML1) is essential for differentiation of
hematopoietic stem cells. The t(8;21) generates the RUNX1-
RUNX1T1 (AML1-ETO) fusion protein that acts as tran-
scriptional repressor and inhibits the expression of AML1
responsive genes. This in turn causes a block in hemato-
poietic stem cell differentiation which in conjunction with
additional genetic events leads to leukemic transformation
[2, 3]. Studies have shown that t(8;21) by itself is incapable
of leukemogenesis and additional genetic events are
necessary for development of AML [4, 5]. Among these
additional genetic changes that cooperate with RUNX1-
RUNX1T1 fusion to cause AML, activating KIT mutations
appear to be the most common. Data suggest that activating
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a role in the development of overt t(8;21)AML [5–8].
Systemic mastocytosis (SM) occurs due to an activating
KIT mutation in a hematopoietic progenitor that leads to
abnormal proliferation and accumulation of neoplastic mast
cells in the bone marrow and other organs. In a subset of
SM termed systemic mastocytosis with associated hemato-
logical non-mast cell disease (SM-AHNMD) in the current
WHO classification, SM coexists with hematologic malig-
nancies that are usually of myeloid origin [1, 9]. SM-
AHNMD comprises 20% of all cases of SM and the most
common associated hematologic malignancies are acute
myeloid leukemia (AML), myelodysplastic syndrome
(MDS), chronic myeloproliferative disorders, and myelo-
dysplastic/myeloproliferative syndromes such as chronic
myelomonocytic leukemia [10–13].
In previous studies, the frequency of KIT mutations
involving exon 17 as represented by a single amino acid
substitution at D816 in patients with t(8;21)(q22;q22) AML
have ranged from 12% to 24.2% [14–17]. Most common
mutations described were at D816 and involved the Asp to
Val substitution (D816V) [14–17]. Other substitutions
included D816H, D816Y, and those at N822 including
N822K and N822T [14–17]. Despite the fact that activating
exon 17 KIT mutations are not uncommon in t(8;21) AML,
a review of published literature suggests that SM associated
with t(8;21) AML is exceedingly rare. Data on such cases
are limited and largely confined to a handful of single case
reports. We report our experience with SM associated with
t(8;21)(q22;q22) AML and review the current literature on
this rare entity.
Materials and methods
Patients with t(8;21) AML who also met WHO criteria for
SM either at initial diagnosis or at relapse were identified
from the databases of our institutions. Additional cases
were identified by PubMed search of the English language
literature as well as from the reference list of the reported
cases [17–20]. Immunohistochemistry for CD117, tryptase,
and CD25 staining was performed using standard techniques.
Polymerase chain reaction (PCR) amplification and direct
sequencing of the exon 17 of the KIT gene were performed
by methods previously described [9]. Briefly, genomic DNA
was isolated from bone marrow specimens using a QiAmp
kit (Qiagen, Valencia, CA, USA). The codon 816-containing
region of the KIT gene was amplified using the primers: 5′-
TGT GAA CAT CAT TCA AGG CGT AC-3′ (forward) and
5′-ACT CAG CCT GTT TCT GGG AAA CTC-3′ (reverse).
PCR conditions were each cycle of 30 s at 93°C, 1 min at
50°C, and 5 min at 72°C for a total of 40 cycles. The
resulting 322-bp product was purified from a 2.5% agarose
gel using a gel extraction kit (Qiagen) and directly
sequenced. On case 3, fluorescence in situ hybridization
(FISH) analysis for t(8;21)(q22;q22) on morphologically
identified bone marrow mast cells (target FISH) was
performed. Briefly, Wright-Giemsa stained bone marrow
aspirate smears were scanned with a Bioview Duet Image
Analyzer (Bioview, Rehovot, Israel) to identify mast cells for
FISH. Following destaining with Carnoy’s fixative and
digestion with pepsin, slides were co-denatured with t(8;21)
probe (Vysis, Downer’s Grove, IL, USA). Slides were
counterstained with DAPI and analyzed on a BioView Duet
Image analyzer. Details of the target FISH technique were
described previously [21].
Results
The clinical and pathologic features of the patients are
summarized in Table 1. Of the ten patients who are
included in this report, cases 1 through 6 were treated at
our institutions and four additional cases (cases 7–10) were
identified from the literature [17–20]. Cases 1, 2, and 3 of
this series were included in previous reports [9, 21].
The patients ranged in age from 26 to 67 years and
included three males and seven females. None of the
patients had urtricaria pigmentosa or other evidence of
extramedullary mast cell involvement except for one
published case that showed hepatic infiltration with mast
cells after AML induction therapy [17]. Symptoms related
to mast cell mediator release were not reported in any of the
patients. All cases had morphologic and immunophenotypic
features of AML with maturation (FAB-M2). Leucocytosis
was present at diagnosis in six of seven patients in whom
initial blood counts were available. Patient 4 had metastatic
breast cancer and had undergone anthracycline-containing
combination chemotherapy. She developed SM with
t(8;21)(q22;q22) AML 1 year after initiation of chemo-
therapy. In nine of the ten cases, increased bone marrow
mast cells were noted at the time of AML diagnosis In case
4, SM was diagnosed following three cycles of consolida-
tion chemotherapy for AML. In that case, the bone marrow
biopsies at diagnosis were reevaluated, but failed to
demonstrate coexisting SM. An activating exon 17 KIT
mutation was detected in seven of nine cases in whom this
data is available. Three patients had D816V, two had D816Y,
and one carried the D816H mutation. In one case (case 6) the
exact mutation was not analyzed while another (case 4)
carried an A814S mutation in addition to D816V. It is
noteworthy that four of the ten cases had chromosome 9q
deletion as an additional cytogenetic abnormality. Of the
eight cases where immunophenotype data on the myeloblasts
was available by flow cytometry, four of eight cases reported
dim expression of CD19 and five of eight cases showed
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30 J Hematopathol (2009) 2:27–33CD56 expression (Table 1). Bone marrow pathology of a
representative case is shown in Fig. 1.
All patients were initially treated with AML induction
chemotherapy that contained an anthracycline and cytarabine.
Four of the ten patients failed to achieve a morphologic
remissionafterinductionchemotherapy.Sixofthetenpatients
have died of progressive or relapsed leukemia and one
patient remains with active disease awaiting allogeneic
HSCT. The two long-term survivors (cases 3 and 10) in
this report had both undergone allogeneic HSCT from
matched siblings after radiation-based high-dose condi-
tioning. In these two patients, recipient-derived bone
marrow mast cells were detected up to a year after HSCT,
but the leukemia remained in durable remission.
Discussion
In this report, we have summarized our experience and
reviewed the published literature on SM that coexists with
t(8;21)(q22;q22) AML. KIT mutations are the most com-
mon additional genetic abnormality in t(8;21) AML and
range in their incidence from 26% to 47% in various reports
[22–24]. However, among the t(8;21) AML with KIT
mutations, the number of cases that have concurrent SM
appears to be extremely rare. Hence, it appears that specific
genetic events in addition to activating KIT mutations and
t(8;21) are required for development of mastocytosis.
Although it can be postulated that these additional genetic
events may promote mast cell differentiation from leukemic
progenitors, the nature of these additional genetic aberra-
tions remains unknown.
Studies examining the relationship between mast cells
and leukemic blasts have shown that the neoplastic mast
cells of SM associated with t(8;21) carry the RUNX1-
RUNX1T1 translocation, thereby proving their derivation
from the leukemic clone. This was demonstrated in case 3
of this series by target FISH, the details of which have been
published elsewhere [21]. Similar findings were noted in
another published case that is included in the current series
(case 10, Nagai et al.) where KIT mutation as well as
RUNX1-RUNX1T1 translocation was detected in recipient-
derived clonal mast cells that persisted after allogeneic
HSCT [20]. In both these cases, the recipient-derived mast
cells gradually declined and the AML remained in
remission. It is unclear if this phenomenon represents
gradual apoptosis of these mast cells or progressive
elimination of leukemic progenitors due to graft-versus-
leukemia effect.
We sought to examine if there were other distinct
cytogenetic or pathologic features that were associated with
SM and t(8;21) AML. Deletion of chromosome 9q was an
additional cytogenetic finding in four of the ten cases. Del
(9q) has been previously reported as part of a complex
phenotype in another case of t(8;21) positive myelomasto-
cytic leukemia (AML with increased bone marrow mast
cells not meeting criteria for SM) [26]. In addition, del (9q)
is the most common additional cytogenetic abnormality in
a
b
c
d
Fig. 1 a Pretreatment bone
marrow aspirate (case 3) show-
ing predominantly myeloblasts
admixed with rare mast cells.
Note the hypergranular cyto-
plasm within the mast cells
(Wright-Giemsa, ×500).
b Day 14 post-treatment bone
marrow aspirate (case 3) with
prominent mast cell infiltrate
(Wright-Giemsa, ×200).
c Immunohistochemistry for
tryptase (case 3) highlights the
mast cell infiltrate (×200).
d Mast cells show expression of
CD25 (case 3), a characteristic
feature of neoplastic mast cells
(×200)
J Hematopathol (2009) 2:27–33 31t(8;21) AML and has been reported in 7–14% of pediatric
cases and 9.7% of adult cases [27]. In comparison, del (9q)
appears to be more frequent in t(8;21) with associated SM,
suggesting that this deletion may play a role in the
pathogenesis of SM. Recently, TLE1 and TLE4 have been
identified as critical genes in the commonly deleted 9q
region in t(8;21) AML [28]. In vitro experiments using
Kasumi-1 cell line showed that these genes behave as
tumor suppressors and knockdown of TLE1 or TLE4
increased the rate of cell division of the AML1-ETO
expressing Kasumi-1 cell line while forced expression of
either caused apoptosis and cell death [28].
The precise incidence of SM coexisting with t(8;21)
AML is unknown. In previous reports, authors have
cautioned that in some cases of AML with coexisting SM,
the diagnosis of SM maybe missed on the initial bone
marrow evaluation due to the excess numbers of blasts
which mask the underlying mast cells and the tendency of
mast cells to localize within stroma of bone marrow
particles in aspirate smears [9]. The bone marrow mast cell
infiltrate appears to become more evident when the
leukemic blasts decrease after therapy as was seen in this
report (Fig. 1b). This prominence of the mast cell infiltrate
after chemotherapy may also be due to the poor sensitivity
of the mast cells to leukemia chemotherapy as evidenced
by their persistence even after high-dose chemotherapy
conditioning for allogeneic HSCT [20]. Infiltration of
extramedullary tissues with mast cells, as well as symptoms
due to mast cell mediator release, appear to be distinctly
uncommon in cases of SM associated with t(8;21) AML.
This may be due to the lack of functionality of these
neoplastic MC as a result of the leukemic aberrations they
carry.
AML with t(8;21)(q22;q22) as the sole cytogenetic
abnormality in general have a favorable outcome when
treated with consolidation regimens containing high-dose
cytarabine [29, 30]; however, studies have shown that only
50% of t(8;21) AML patients are alive at 5 years [27].
D816 KIT mutations were detected in 10.5% of patients
with t(8;21) AML in one study [17]. The presence of KIT
mutations (D816 and others) may explain the poor
prognosis of a subset of t(8;21) patients as activating exon
17 KIT mutations have now been shown to be a major
adverse prognostic factor for event-free and overall survival
in t(8;21) AML [14–17] and a predictor of higher relapse
risk [15]. The number of patients with mutant KIT who had
SM in addition has not been reported in any of these
studies, which may be an indicator of its extreme rarity.
Interestingly, in previous studies it has been reported that
91–100% of t(8;21) AML patients with KIT mutations
achieved complete remission after chemotherapy [15, 25].
However, in our current series induction failure occurred in
four of ten patients. This observation again re-emphasizes
the fact that SM associated with AML has a grave
prognosis.
It is worth noting that of the ten patients (Table 1) only
two patients achieved a durable remission of AML. Both of
these patients had undergone allogeneic HSCT. One of our
patients (case 3) is in continuous remission 4 years after
allogeneic HSCT. Sperr et al. have reported a patient with
myelomastocytic leukemia and t(8;21) AML who relapsed
after a reduced intensity HSCT, but achieved a lasting
remission following high-dose conditioning and a second
HSCT from the same donor, thereby suggesting that
conditioning intensity may be important [26]. Although
data are very limited, the dismal results with conventional
chemotherapy suggests that allogeneic HSCT should be an
early consideration in SM associated with t(8;21) AML in
patients who are suitable candidates. The D816V KIT
mutation is resistant to the tyrosine kinase inhibitor imatinib
[31]. Dasatinib, to which KIT D816V is sensitive, may have
a role in the therapy of these cases as evidenced by in vitro
data as well as its in vivo activity of this drug in recent
reports of SM, including a patient with SM-AML [32–34].
Other tyrosine kinase inhibitors like midostaurin (PKC 412)
and nilotinib (AMN 107)) that are capable of inhibiting
activating KIT D816V may also have potential in the
treatment of t(8;21) AML that carry this mutation [35, 36].
In conclusion, SM associated with t(8;21) AML is
extremely rare and carries a dismal prognosis. During
evaluation of t(8;21)(q22;q22) AML, care should be taken
to look for coexisting SM in the initial and subsequent bone
marrow specimens since the mast cell infiltrate may be
subtle and easily overlooked. This will help identify a
subset of t(8;21) AML patients with a particularly poor
prognosis.
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